Pulmonary embolism (PE) remains a major clinical problem associated with considerable mortality and morbidity. In patients with PE, appropriate anticoagulant therapy has been shown to significantly reduce both recurrence and mortality. Low-molecular-weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the treatment of PE, with a similar risk of bleeding. Furthermore...

Seven pharmaceutical heparins were investigated by oligosaccharide mapping by digestion with heparin lyase 1, 2, or 3, followed by high performance liquid chromatography analysis. The structure of one of the prepared mapping standards, ΔUA-Gal-Gal-Xyl-O-CH(2)CONHCH(2)COOH (where ΔUA is 4-deoxy-α-l-threo-hex-4-eno-pyranosyluronic acid, Gal is β-d-galactpyranose, and Xyl is β-d-xylopyranose) rele...

Venous thromboembolism (VTE), in particular pulmonary embolism (PE), remains the leading cause of death among pregnant women. Low-molecular-weight heparin (LMWH), with preference for therapeutic doses given twice daily according to European guidelines, is drug choice treatment VTE pregnancy and puerperium. The recommended dose calculated on early body weight. Evidence support anti-Xa monitoring...

T here are no evidence based studies dealing with the incidence of venous sheath related thrombosis and the role of heparin, particularly in the setting of prolonged procedures with multiple lines. The clinical importance of catheter related thrombosis remains undefined in the setting of electrophysiological studies (EPS). We sought to determine the incidence of multiple venous sheath related t...

www.pharmtech.com arenteral low molecular weight heparin (LMWH) has replaced warfarin as the standard of care for the prevention of deep vein thrombosis (DVT) and pulmonary embolism in high-risk, hospitalized patients undergoing joint replacement or abdominal surgery (1). LMWH is favored over antivitamin K oral anticoagulants such as warfarin because it produces a rapid onset of anticoagulant a...

Long-term heparin treatment causes osteoporosis through, an as yet, undefined mechanism. To investigate this phenomenon and to determine the relative benefits of low-molecular-weight heparin (LMWH) use, we treated rats with once daily subcutaneous injections of either unfractionated heparin (1.0 U/g or 0.5 U/g), the LMWH, Tinzaparin (1.0 U/g or 0.5 U/g), or placebo (saline) for a period of 32 d...

Heparin and its low-molecular-weight heparin (LMWH) derivatives are widely used clinical anticoagulants. These drugs are critical for the practice of medicine in applications including kidney dialysis, cardiopulmonary bypass, and in the management of venous thromboembolism. Currently, these drugs are derived from livestock, primarily porcine intestine. The worldwide dependence on a single anima...

Hypercoagulability is a common complication of the systemic inflammation related to coronavirus disease 2019 creating debate within critical care community on therapeutic utility Low Molecular Weight Heparin (LMWH). We collected data consecutive patients with COVID-19 admitted Emergency Department Castel San Giovanni Hospital, between February 29th and April 7th, 2020. Exclusion criteria were a...

Cancer is a risk factor for venous thromboembolism (VTE). This risk is amplified by treatment with chemotherapy, radiation, or surgery. Thus, patients with cancer undergoing major surgery should receive appropriate prophylaxis. Available agents include low-dose unfractionated heparin (LDUH), low-molecular-weight heparin (LMWH), and Factor Xa inhibitors. Recent data suggest that Factor Xa inhibi...

Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of venous thromboembolic events (VTE) is readily accomplished. The introduction of low-molecular-weight heparin (LMWH) approximately two decades ago (in ...